Search results
Results from the WOW.Com Content Network
Cologuard refers to an at-home stool DNA test that can help screen for colon cancer or polyps.A person enrolled in Medicare aged between 45 and 85 is eligible for coverage for a Cologuard test ...
The fecal immunochemical test (FIT) is a diagnostic technique that examines stool samples for traces of non-visible blood, which could potentially indicate conditions including bowel cancer. [1] Symptoms which could be caused by bowel cancer and suggest a FIT include a change in bowel habit, anaemia , unexplained weight loss, and abdominal pain .
The American College of Gastroenterology has recommended the abandoning of gFOBT testing as a colorectal cancer screening tool, in favor of the fecal immunochemical test (FIT). [3] The newer and recommended tests look for globin, DNA, or other blood factors including transferrin, while conventional stool guaiac tests look for heme.
Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A ...
The other screening tests include flexible sigmoidoscopy, double-contrast barium enema, computed tomographic (CT) colonography (virtual colonoscopy), guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and multitarget stool DNA screening test (Cologuard).
For premium support please call: 800-290-4726 more ways to reach us
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Exact Sciences (EXAS) has pre-announced first quarter results, with total revenue up 114% year-over-year at $348 million, surpassing the Street estimate of $342.6 million.The company, which ...